# Natural Compounds and Histone Deacetylase Inhibitors: A Combined Approach Against mCRPC Cells

**Authors:** Janiah Alimudin, Zeynep Betts, Asuman Deveci Ozkan

PMC · DOI: 10.3390/biomedicines13020296 · Biomedicines · 2025-01-25

## TL;DR

This study explores combining sodium butyrate and rutin to fight prostate cancer cells, showing improved anticancer effects.

## Contribution

The first evaluation of sodium butyrate and rutin combination therapy in mCRPC cells.

## Key findings

- Combined treatment significantly reduced cell viability compared to individual treatments.
- Enhanced apoptosis and increased ROS levels were observed in combination-treated cells.

## Abstract

Background: Sodium butyrate (NaBu), a short-chain fatty acid, modulates global gene expression through histone deacetylase (HDAC) inhibition, suppressing proliferation and inducing apoptosis in various cancers. Rutin (RUT), a polyphenolic flavonoid found in many plants, exhibits notable anticancer properties. Combining chemotherapeutic agents with natural polyphenols represents a promising strategy for cancer therapy. This study aims to evaluate, for the first time, the potential effects of NaBu and RUT combination therapy on metastatic castration-resistant prostate cancer (mCRPC) cells. Methods: PC-3 cells were treated with varying concentrations of NaBu, RUT, and their combinations. Cell viability was assessed using the WST-1 assay. Based on combination index values, selected treatments were further analyzed for apoptosis (Annexin V assay), intracellular reactive oxygen species (ROS) production, mRNA expression levels, and changes in cell and nuclear morphology. Results: The combined treatment of NaBu and RUT significantly reduced cell viability compared to individual treatments. Enhanced apoptotic induction and elevated ROS levels were observed in combination-treated cells, alongside notable changes in cellular and nuclear morphology and mRNA expression levels. Conclusions: NaBu and RUT combination therapy exhibits a synergistic anticancer effect in mCRPC cells by inhibiting cell viability, inducing apoptosis, and increasing ROS production. These findings suggest a promising therapeutic approach that warrants further investigation to elucidate the underlying molecular mechanisms and assess its potential in preclinical and clinical settings.

## Linked entities

- **Chemicals:** Sodium butyrate (PubChem CID 264), Rutin (PubChem CID 5280805)

## Full-text entities

- **Genes:** ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, HDAC9 (histone deacetylase 9) [NCBI Gene 9734] {aka HD7, HD7b, HD9, HDAC, HDAC7B, HDAC9B}
- **Diseases:** castration-resistant prostate cancer (MESH:D064129), cancer (MESH:D009369)
- **Cell lines:** PC-3 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0035)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11853668/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11853668/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC11853668/full.md

---
Source: https://tomesphere.com/paper/PMC11853668